Congresses

Summary of thromboembolic (TE) or thrombotic microangiopathy (TMA) events in persons taking emicizumab

Oral presentation P131: Lee L, Moreno K, Kuebler P, et al.

Go to Document

Bone and joint health markers in persons with hemophilia A treated with emicizumab in HAVEN 3

Oral presentation: Kiialainen A, Niggli M, Kempton C, et al.

Go to Document

Real-world treatment patterns, health outcomes, and healthcare resource use among persons with hemophilia A

Poster presentation 15: Caplan EO, Patel AM, DeClue R, et al.

Go to Document

An insight into clinical outcomes in mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study

Oral presentation OC 09.3: Nissen F, Burke T, Asghar S, et al.

Go to Document

Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors

Oral presentation OC 60.1: Santagostino E, Oldenburg J, Chang T, et al.

Go to Document

Timing of treated spontaneous bleeding in persons with haemophilia A receiving emicizumab prophylaxis 6 mg/kg once every 4 weeks

Poster presentation P191: Pipe SW, Ko RH, Chang T, et al.

Go to Document

Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data

Poster presentation P-1133: Faghmous I, Flores C, Sarouei K, et al.

Go to Document

Surgical experience from the Phase III STASEY trial of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors: Data from the second interim analysis

Poster presentation PB0939: Castaman G, Kremer Hovinga JA, Schutgens R, et al.

Go to Document

An analysis of fatalities in persons with congenital hemophilia A reported in the FDA Adverse Event Reporting System (FAERS) database

Poster presentation 25: De Ford C, Kuebler P, Shang A, et al.

Go to Document

Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies

Oral presentation OC 60.2: Callaghan M, Negrier C, Paz-Priel I, et al.

Go to Document

A survey study of hematologists in the United States to understand disease management of patients with hemophilia A treated with emicizumab

Poster presentation P205: Owens WE, Patel AM, Poulos K, et al.

Go to Document

Factor VIII use in the treatment of breakthrough bleeds in hemophilia A patients without inhibitors on emicizumab prophylaxis: the phase 3 HAVEN 3 study experience

Poster presentation P-2395: Callaghan M, Trzaskoma B, Ko RH, et al.

Go to Document

A contemporary framework for understanding mortality in people with congenital hemophilia A (PwcHA)

Poster presentation 23: Pipe SW, Kruse-Jarres R, Mahlangu JN, et al.

Go to Document

Pharmacokinetics and coagulation biomarkers in persons with hemophilia A (PwHA) and FVIII inhibitors receiving emicizumab in the Phase IIIb STASEY study

Poster presentation PB0942: Kiialainen A, Petry C, Jiménez-Yuste V, et al.

Go to Document

A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results

Oral presentation OC 60.3: Jimenez-Yuste V, Klamroth R, Castaman G, et al.

Go to Document

Estimating the burden of intracranial hemorrhage in persons with hemophilia A using administrative claims data.

Poster presentation P-2398: Mahajerin A, Patel AM, Yang E, et al.

Go to Document

Associations between physical activity levels and bleeding frequency in people with mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study

Poster presentation PB0943: Nissen F, Burke T, Asghar S, et al.

Go to Document

Characteristics of persons with hemophilia A treated with emicizumab with or without factor VIII inhibitors

Poster presentation 31: Mahajerin A, Yang E, Patel AM, et al.

Go to Document

Joint bleeds in paediatric patients with haemophilia A: a CHESS study analysis

Oral presentation OC 70.1: Castro FA, Silkey M, Khair K, et al.

Go to Document

A systematic review of mortality statistics and causes of death in people with congenital hemophilia A (PwcHA)

Poster presentation 32: Hay CR, Nissen F, Pipe SW

Go to Document

Long-term safety and efficacy for up to >5 years in a phase 1/2 study in patients with severe hemophilia A

Poster Presentaton PB0950: Shima M, Nagao A, Taki M, et al.

Download PDF

Analytical performance evaluation of a dedicated calibrator and controls for emicizumab quantification

Oral presentation OC 07.4: Ramamurthy N, Kucharski C, McInerney M, et al.

Go to Document

Summary of thrombotic events or thrombotic microangiopathy events in persons taking emicizumab

Poster presentation 35: Lee L, Moreno K, Kuebler P, et al.

Go to Document

A randomized, multicenter, open-label, Phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-Pacific region (HAVEN 5)

Poster presentation PB0957: Wang S, Zhao X, Wang X, et al.

Go to Document

Early patient experiences with emicizumab in the United States: a qualitative study

Poster presentation PB0244: Markowitz JT, Patel AM, Raimundo K, et al.

Go to Document

Second interim analysis results from the STASEY trial: A single-arm, multicenter, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in people with hemophilia A (PwHA) with FVIII inhibitors.

Poster presentation PB0958: Jiménez-Yuste V, Klamroth R, Castaman G, et al.

Go to Document

Bone and joint health markers in persons with hemophilia A (PwHA) treated with emicizumab in the HAVEN 3 clinical trial

Poster presentation 36: Kiialainen A, Niggli M, Kempton C, et al.

Go to Document

Evaluating Patient and Caregiver Treatment Preferences in Hemophilia A Using a Discrete Choice Experiment

Poster presentation PB0245: Benton M, Shi L, Patel AM, et al.

Go to Document

Health-Related Quality of Life in Paediatric Patients With Haemophilia A

Poster presentation PB0250: Castro FA, Silkey M, Khair K, et al.

Go to Document

Exposure–response modeling of emicizumab for the prophylaxis of bleeding in haemophilia A patients with and without inhibitors against factor VIII

Poster presentation PB0325: Jonsson F, Schmitt C, Petry C, et al.

Go to Document

Timing of treated spontaneous bleeding in persons with haemophilia A (PwHA) in the HAVEN 3 study

Poster presentation PB0694: Mahlangu J, Oldenburg J, O’Connell N, et al.

Go to Document

Emicizumab prophylaxis improves long-term Physical Health Scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies

Poster presentation PB0698: Skinner M, Negrier C, Paz-Priel I, et al.

Go to Document

Treatment Patterns and Outcomes in Persons with Hemophilia A (PwHA): Analysis from the CHOICE Survey in the United States

Poster presentation PB1404: Patel AM, Cyhaniuk A, Raimundo K, et al.

Go to Document

Emicizumab pediatric experience in clinical studies and beyond

Oral presentation: Levy G.

Go to Document

Factor VIII use in the treatment of breakthrough bleeds in persons with hemophilia A without inhibitors on emicizumab prophylaxis: The phase III HAVEN 3 study experience

Poster Presentation: Callaghan M, Trzaskoma B, Ko RH, et al.

Go to Document

Early patient experiences with emicizumab in the United States: a qualitative study

Poster Presentation: Markowitz JT, Patel AM, Raimundo K, et al.

Go to Document

Congresses

The below Genentech/Roche-sponsored congress posters and oral presentations include data presented at scientific meetings from mid-2019 onwards. Click the below links for congress publications of interest.